Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000182719 | SCV000235101 | uncertain significance | not provided | 2012-08-13 | criteria provided, single submitter | clinical testing | p.Leu1410Pro (CTT>CCT):c.4229 T>C in exon 32 of the RYR2 gene (NM_001035.2). The Leu1410Pro variant in the RYR2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Leu1410Pro results in a semi-conservative amino acid substitution of one non-polar residue for another at a position that is conserved across species. However, in silico analysis predicts Leu1410Pro is benign to the protein structure/function. Similarly, Leu1410Pro does not occur in any of the hotspot regions of the RYR2 gene, and no mutations in surrounding residues have been reported in association with CPVT, indicating this region of the protein may be tolerant of change. Nevertheless, the NHLBI ESP Exome Variant Server reports Leu1410Pro was not observed in approximately 6,000 samples from individuals of European and African American backgrounds, indicating it is not a common benign variant in these populations. With the clinical and molecular information available at this time, we cannot definitively determine if Leu1410Pro is a disease-causing mutation or a rare benign variant. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is characterized by syncope, typically beginning in the first decade of life, which may be triggered by physical activity or intense emotion. In patients with CPVT, stress-induced release of catecholamines causes a dysfunction of the calcium-ion channel in the myocytes (De La Fuente et al., 2008; Napolitano C et al., 2012; Priori S et al., 2002). CPVT is primarily caused by autosomal dominant mutations in the RYR2 and KCNJ2 genes. Less commonly, CPVT is caused by autosomal recessive mutations in the CASQ2 gene (Napolitano C et al., 2012). Approximately 50% of patients with autosomal dominant CPVT have been reported to have a mutation in the RYR2 gene, while mutations in the RYR2 gene associated with ARVC are rare (McNally E et al., 2009; Napolitano C et al., 2012). The variant is found in CPVT panel(s). |
| Fulgent Genetics, |
RCV002485213 | SCV002789187 | uncertain significance | Arrhythmogenic right ventricular dysplasia 2; Catecholaminergic polymorphic ventricular tachycardia 1; Ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome | 2021-11-10 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV002515325 | SCV002985547 | uncertain significance | Catecholaminergic polymorphic ventricular tachycardia 1 | 2022-06-01 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 1410 of the RYR2 protein (p.Leu1410Pro). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RYR2 protein function. ClinVar contains an entry for this variant (Variation ID: 201244). This variant has not been reported in the literature in individuals affected with RYR2-related conditions. This variant is not present in population databases (gnomAD no frequency). |